Stocks Health care BCRX
NASDAQ · Health careBiocryst Pharmaceuticals Inc (BCRX)
Biocryst Pharmaceuticals Inc brought in $940.6M of revenue over the twelve months to June 30, 2026, up 68.7% from a year earlier. It posted a net loss of $384.7M. Operating cash flow minus capital spending left $344.9M of free cash flow in fiscal 2025. At June 30, 2026 it held $155M in cash against $395.4M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Biocryst Pharmaceuticals Inc does
Biocryst Pharmaceuticals Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker BCRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $874.8M | $263.9M | $1.21 | $344.9M |
| 2024 | $450.7M | -$88.9M | -$0.43 | -$53.1M |
| 2023 | $331.4M | -$226.5M | -$1.18 | -$97.3M |
| 2022 | $270.8M | -$247.1M | -$1.33 | -$163.2M |
| 2021 | $157.2M | -$184.1M | -$1.03 | -$144.5M |
| 2020 | $17.8M | -$182.8M | -$1.09 | -$135.6M |
Latest SEC filings
What Biocryst Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- August 4, 2026Restructuring or layoffs 8-K/A
- June 29, 2026
- June 12, 2026
- May 12, 2026Passive stake (5% or more) SCHEDULE 13G
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026
Questions about BCRX
What does Biocryst Pharmaceuticals Inc do?
Biocryst Pharmaceuticals Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker BCRX.
Is Biocryst Pharmaceuticals Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $384.7M on revenue of $940.6M.
How much revenue does Biocryst Pharmaceuticals Inc make?
Over the twelve months to June 30, 2026 Biocryst Pharmaceuticals Inc reported revenue of $940.6M. That is 68.7% more than a year earlier.
When did Biocryst Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 2, 2026.
Similar companies
Follow BCRX
Get an email when Biocryst Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow BCRX: get an email when it filesWhere the numbers come from
Financial figures are the values Biocryst Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.